Related Experiment Video
Updated: Dec 13, 2025

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
Published on: February 28, 2025
Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
Seri Jo1, Suwon Kim1, Dae Yong Kim2
1College of Pharmacy, Graduates School of Pharmaceutical Sciences, Ewha W. University, Seoul, Republic of Korea.
Abstract:
Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the good targets to find antiviral agents before vaccines are available. Some flavonoids are known to inhibit 3CLpro from SARS-CoV which causes SARS. Since their sequence identity is 96%, a similar approach was performed with a flavonoid library. Baicalin, herbacetin, and pectolinarin have been discovered to block the proteolytic activity of SARS-CoV-2 3CLpro. An in silico docking study showed that the binding modes of herbacetin and pectolinarin are similar to those obtained from the catalytic domain of SARS-CoV 3CLpro. However, their binding affinities are different due to the usage of whole SARS-CoV-2 3CLpro in this study. Baicalin showed an effective inhibitory activity against SARS-CoV-2 3CLpro and its docking mode is different from those of herbacetin and pectolinarin. This study suggests important scaffolds to design 3CLpro inhibitors to develop antiviral agents or health-foods and dietary supplements to cope with SARS-CoV-2.
Insights
Certain flavonoids, including baicalin, herbacetin, and pectolinarin, show potential as inhibitors against the SARS-CoV-2 main protease (3CLpro). This research identifies key compounds for developing new antiviral agents and health supplements to combat COVID-19.
Area of Science:
- Biochemistry
- Pharmacology
- Virology
Background:
- The COVID-19 pandemic necessitates the development of effective antiviral treatments.
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (3CLpro) is a critical target for antiviral drug discovery.
- Flavonoids have demonstrated inhibitory activity against SARS-CoV 3CLpro, suggesting potential for SARS-CoV-2.
Purpose of the Study:
- To identify flavonoids that inhibit the proteolytic activity of SARS-CoV-2 3CLpro.
- To investigate the binding modes and affinities of potential flavonoid inhibitors using computational methods.
- To suggest structural scaffolds for designing novel antiviral agents targeting SARS-CoV-2.
Main Methods:
- Screening of a flavonoid library for inhibitory activity against SARS-CoV-2 3CLpro.
- Utilizing *in silico* molecular docking studies to analyze binding interactions.
- Comparing docking results with known interactions against SARS-CoV 3CLpro.
Main Results:
- Baicalin, herbacetin, and pectolinarin were identified as inhibitors of SARS-CoV-2 3CLpro.
- Herbacetin and pectolinarin exhibited binding modes similar to those observed with SARS-CoV 3CLpro.
- Baicalin demonstrated effective inhibition with a distinct binding mode, suggesting unique inhibitory mechanisms.
Conclusions:
- Baicalin, herbacetin, and pectolinarin are promising candidates for developing SARS-CoV-2 antiviral therapies.
- The identified flavonoids provide valuable scaffolds for designing potent 3CLpro inhibitors.
- This research supports the development of antiviral agents, health foods, and dietary supplements for managing SARS-CoV-2 infections.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Antimicrobial Effectiveness
Subviral Agents
Enzyme Inhibition
Cancer Prevention
Some...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

